0 43

Cited 0 times in

Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial

 Mukul Sharma  ;  Robert G Hart  ;  Eric E Smith  ;  Jackie Bosch  ;  Fei Yuan  ;  Amparo Casanova  ;  John W Eikelboom  ;  Stuart J Connolly  ;  Gloria Wong  ;  Rafael Diaz  ;  Patricio Lopez-Jaramillo  ;  Georg Ertl  ;  Stefan Sto¨rk  ;  Gilles R Dagenais  ;  Eva M Lonn  ;  Lars Ryden  ;  Andrew M Tonkin  ;  John D Varigos  ;  Deepak L Bhatt  ;  Kelley RH Branch  ;  Jeffrey L Probstfield  ;  Jae-Hyung Kim  ;  Jong-Won Ha  ;  Martin O’Donnell  ;  Dragos Vinereanu  ;  Keith AA Fox  ;  Yan Liang  ;  Lisheng Liu  ;  Jun Zhu  ;  Nana Pogosova  ;  Aldo P Maggioni  ;  Alvaro Avezum  ;  Leopoldo S Piegas  ;  Katalin Keltai  ;  Matyas Keltai  ;  Nancy Cook Bruns  ;  Scott Berkowitz  ;  Salim Yusuf 
 INTERNATIONAL JOURNAL OF STROKE, Vol.14(3) : 270-281, 2019 
Journal Title
Issue Date
Magnetic resonance imaging ; anticoagulant ; clinical trial ; cognition ; prevention ; silent infarct
BACKGROUND: Covert vascular disease of the brain manifests as infarcts, white matter hyperintensities, and microbleeds on MRI. Their cumulative effect is often a decline in cognition, motor impairment, and psychiatric disorders. Preventive therapies for covert brain ischemia have not been established but represent a huge unmet clinical need. AIMS: The MRI substudy examines the effects of the antithrombotic regimens in COMPASS on incident covert brain infarcts (the primary outcome), white matter hyperintensities, and cognitive and functional status in a sample of consenting COMPASS participants without contraindications to MRI. METHODS: COMPASS is a randomized superiority trial testing rivaroxaban 2.5 mg bid plus acetylsalicylic acid 100 mg and rivaroxaban 5 mg bid against acetylsalicylic acid 100 mg per day for the combined endpoint of MI, stroke, and cardiovascular death in individuals with stable coronary artery disease or peripheral artery disease. T1-weighted, T2-weighted, T2*-weighted, and FLAIR images were obtained close to randomization and near the termination of assigned antithrombotic therapy; biomarker and genetic samples at randomization and one month, and cognitive and functional assessment at randomization, after two years and at the end of study. RESULTS: Between March 2013 and May 2016, 1905 participants were recruited from 86 centers in 16 countries. Of these participants, 1760 underwent baseline MRI scans that were deemed technically adequate for interpretation. The mean age at entry of participants with interpretable MRI was 71 years and 23.5% were women. Coronary artery disease was present in 90.4% and 28.1% had peripheral artery disease. Brain infarcts were present in 34.8%, 29.3% had cerebral microbleeds, and 93.0% had white matter hyperintensities. The median Montreal Cognitive Assessment score was 26 (interquartile range 23-28). CONCLUSIONS: The COMPASS MRI substudy will examine the effect of the antithrombotic interventions on MRI-determined covert brain infarcts and cognition. Demonstration of a therapeutic effect of the antithrombotic regimens on brain infarcts would have implications for prevention of cognitive decline and provide insight into the pathogenesis of vascular cognitive decline.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Ha, Jong Won(하종원) ORCID logo https://orcid.org/0000-0002-8260-2958
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.